MEDIORG Stock Overview
Develops, manufactures, and distributes a range of generic pharmaceutical dosage for government and private institutions as contract manufacturer/third party manufacturer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Medicamen Organics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹151.90 |
| 52 Week High | ₹151.90 |
| 52 Week Low | ₹130.95 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 360.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDIORG | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | n/a | 0.9% | 1.1% |
| 1Y | n/a | 46.8% | 44.4% |
Return vs Industry: Insufficient data to determine how MEDIORG performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MEDIORG performed against the Indian Market.
Price Volatility
| MEDIORG volatility | |
|---|---|
| MEDIORG Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: MEDIORG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MEDIORG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 62 | Bal Gupta | www.medicamenorganics.com |
Medicamen Organics Limited develops, manufactures, and distributes a range of generic pharmaceutical dosage for government and private institutions as contract manufacturer/third party manufacturer. It offers anti-bacterial, anti diarrheal, anti-fungal, anti-malarial, anti diabetic, dental cure, proton pump inhibitor, anti protozoal, anti histamine, anti-hypertensive, anti lipidemic, multivitamin, multimineral, and non-steroidal anti-inflammatory drugs in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. The company markets its products across India, as well as various African, CIS, and southeast Asian countries.
Medicamen Organics Limited Fundamentals Summary
| MEDIORG fundamental statistics | |
|---|---|
| Market cap | ₹1.78b |
| Earnings (TTM) | ₹24.04m |
| Revenue (TTM) | ₹252.72m |
73.9x
P/E Ratio7.0x
P/S RatioIs MEDIORG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDIORG income statement (TTM) | |
|---|---|
| Revenue | ₹252.72m |
| Cost of Revenue | ₹157.99m |
| Gross Profit | ₹94.73m |
| Other Expenses | ₹70.69m |
| Earnings | ₹24.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.05 |
| Gross Margin | 37.49% |
| Net Profit Margin | 9.51% |
| Debt/Equity Ratio | 83.4% |
How did MEDIORG perform over the long term?
See historical performance and comparison